NASDAQ | DRNA

$2.75 - 0.08 (-2.827%)

3 month stock price graph

3:59 PM ET on Aug 22, 2017 Pricing delayed 20 minutes

Investors & Media

Press Releases

 
Press Releases
  Date Title and Summary View
Mar 30, 2017
Provides Sufficient Cash into 2019 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that it has signed a stock purchase agreement...
Mar 27, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate update at the BioCentury 24t...
Mar 23, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its fourth quarter and full year 2016 financial results after market close on Thursday, March 30,...
Mar 1, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Cowen and Company 37th An...
Feb 8, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in an analyst-led fireside chat at the Leerink Par...
Feb 2, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that on January 31, 2017, the Compensation Committee of the Company's Board of Directors approved the grant of an inducement stock ...
Nov 9, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Stifel 2016 Healthcare Conference on Wednesday,...
Nov 7, 2016
Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today reported financial and operational results for the third quarter ended...
Oct 31, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2016 financial results after market close on Monday, November 7, 2016. ...
Sep 26, 2016
Primary Hyperoxaluria Development Program Transitioned From DCR-PH1 to Subcutaneously Delivered GalXC Candidate DCR-PHXC Clinical Development Discontinued for DCR-MYC in Oncology Indications CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DR...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase